Scholarlink

Introduction <p>Several studies have explored different doses of checkpoint inhibitors in various malignancies, but the optimal dose remains undefined. Here, we present our data on the use of low-dose Nivolumab (LD-Nivo) in combination with conventional chemotherapy for patients with Relapsed/Refractory Hodgkin lymphoma (RRHL).</p> Methods <p>All patients with RRHL who received LD-Nivo with conventional chemotherapy between 2020 and 2024 were included in the study. All patients received a fixed dose of 40&#xa0;mg of Nivolumab per cycle.</p> Results <p>Twenty-one patients were included in the study with a median age of 26&#xa0;years. The majority of patients had refractory disease (n = 16; 76.2%). Median Nivolumab dose per cycle was 0.66&#xa0;mg/kg and median number of cycles of therapy was 3. The overall response rate was 100% with 19 patients achieving a complete response (90.5%). Eleven patients (52.4%) underwent an Autologous hematopoietic cell transplant post salvage therapy. The median follow-up was 23&#xa0;months during which 2 patients relapsed. There were no deaths during follow-up. Median progression-free and overall survival were not reached.</p> Conclusion <p>The addition of a fixed 40&#xa0;mg dose of Nivolumab to conventional salvage therapy has demonstrated high response rates and favourable outcomes. This may serve as a viable option in Low/Middle Income Countries.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Addition of Low Dose Nivolumab to Salvage Chemotherapy in Patients with Relapsed/Refractory Hodgkin Lymphoma

  • 期刊论文

  • 发表日期：

    2025年7月25日

查看全文
  • Charanpreet Singh,
  • K. S. Lekshmon,
  • Arihant Jain,
  • Deepesh Lad,
  • Alka Khadwal,
  • Rajender Basher,
  • Amanjit Bal,
  • Radhika Srinivasan,
  • Pankaj Malhotra,
  • Gaurav Prakash

摘要

Introduction

Several studies have explored different doses of checkpoint inhibitors in various malignancies, but the optimal dose remains undefined. Here, we present our data on the use of low-dose Nivolumab (LD-Nivo) in combination with conventional chemotherapy for patients with Relapsed/Refractory Hodgkin lymphoma (RRHL).

Methods

All patients with RRHL who received LD-Nivo with conventional chemotherapy between 2020 and 2024 were included in the study. All patients received a fixed dose of 40 mg of Nivolumab per cycle.

Results

Twenty-one patients were included in the study with a median age of 26 years. The majority of patients had refractory disease (n = 16; 76.2%). Median Nivolumab dose per cycle was 0.66 mg/kg and median number of cycles of therapy was 3. The overall response rate was 100% with 19 patients achieving a complete response (90.5%). Eleven patients (52.4%) underwent an Autologous hematopoietic cell transplant post salvage therapy. The median follow-up was 23 months during which 2 patients relapsed. There were no deaths during follow-up. Median progression-free and overall survival were not reached.

Conclusion

The addition of a fixed 40 mg dose of Nivolumab to conventional salvage therapy has demonstrated high response rates and favourable outcomes. This may serve as a viable option in Low/Middle Income Countries.